IL -17 inhibitors have established a high standard for efficacy in moderate to severe psoriasis, placing pressure on current therapies that are less efficacious and a great number of investigational therapies that are still in the pipeline. While dermatologists are becoming more comfortable prescribing an IL -17 inhibitor before TNF inhibitors, Humira, a TNF inhibitor, remains the most prescribed therapy in this highly competitive market. However, opportunity exists for emerging therapies to differentiate themselves by addressing important unmet needs that are identified in this analysis.
Questions Answered:

What are the treatment drivers and goals for moderate to severe psoriasis?
What attributes are key influencers, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for moderate to severe psoriasis?
What are the prevailing areas of unmet need and opportunity in moderate to severe psoriasis?
What trade-offs across different clinical attributes and price are acceptable to and European dermatologists for a hypothetical new moderate to severe psoriasis drug?

Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60  and 30 European dermatologists fielded in February and March 2017
Key companies:   AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis
Key drugs:  Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz

Related Reports

Psoriasis | Landscape & Forecast | Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-a...

View Details

Psoriasis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - Palmoplantar Pustular Psoriasis/Generalized Pustular Psoriasis (US )

MARKET OUTLOOK Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP])...

View Details

Psoriasis | Access and Reimbursement | US | 2018

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (

View Details

Psoriasis | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbr...

View Details